KUALA LUMPUR: Ho Wah Genting Bhd has submitted a letter to the Ministry of Science, Technology and Innovation Malaysia to explore potential collaboration on its research study and distribution of E-Mo Covid-19 Vaccine developed by E-Mo Biology Inc (EBI) upon approval by US Food And Drug Administration being obtained.
Ho Wah, in a statement today, said the potential collaboration would support its participation through subsidiary HWGB Biotech Sdn Bhd in research study on the Covid-19 vaccine.
"It is also a positive step for HWGB Biotech efforts to plan for the distribution of EBI's E-Mo Covid-19 vaccine in Malaysia. It is HWGB Biotech's aim to provide a safe, affordable and easily accessible vaccine to ensure the well-being of all Malaysians and to significantly reduce the number of Covid-19 cases in the country," it added.
HWGB Biotech general manager of medical and pharmaceutical research, Dr. Yaman Walid Kassab said when successful, it can help the local economy recover quicker and hopefully open borders to other countries or cities for leisure and business purposes, following in the footsteps of Singapore and Hong Kong.
"In light of the current Covid-19 situation in Malaysia, it is imperative for us to work fast to provide a safe, affordable and easily accessible vaccine for the masses to ensure immunity to Covid-19," he added.